{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:33:56Z","timestamp":1784619236286,"version":"3.55.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Venetoclax is highly active in previously treated Waldenstr\u00f6m macroglobulinemia (WM). However, data on the long-term durability and retreatment with venetoclax remain limited. Herein, we present an update of a prospective clinical trial of finite-duration venetoclax on 32 previously treated patients with WM. With a median follow-up of 81 months, 23 patients (72%) had disease progression, 17 (53%) began a new treatment, and 3 (9%) had died. The median progression-free survival (PFS) was 36 months, and the median treatment-free survival (TFS) was 43 months. PFS and TFS were superior in patients who attained at least a partial response to therapy. CXCR4 mutations or previous Bruton tyrosine kinase inhibitor exposure did not impact these outcomes. Of the 17 patients who started a new therapy after completion of venetoclax therapy, 9 were retreated with venetoclax alone or in combination with other treatments (3 attained a very good partial response, 4 attained a partial response, 1 had stable disease, and 1 did not respond). No BCL2 G101V mutations were detected in 52 CD19-selected bone marrow samples from 27 patients during treatment. Venetoclax induced durable responses in WM, thereby enabling retreatment in patients who progressed after completing therapy without the emergence of BCL2 G101V mutations. This trial was registered at www.ClinicalTrials.gov as #NCT02677324.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016890","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:05:50Z","timestamp":1752786350000},"page":"4842-4847","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-6643","authenticated-orcid":false,"given":"Alberto","family":"Guijosa","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Medical Oncology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3219-2292","authenticated-orcid":false,"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"5Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Flynn","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Meid","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Budano","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9637-4221","authenticated-orcid":false,"given":"Andres","family":"Ramirez-Gamero","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Roger Williams Medical Center, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Tsakmaklis","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1689-1691","authenticated-orcid":false,"given":"Zachary R.","family":"Hunter","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6735","authenticated-orcid":false,"given":"Shayna","family":"Sarosiek","sequence":"additional","affiliation":[{"name":"1Bing Center for Waldenstr\u00f6m Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"1","key":"2025101409214465500_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025101409214465500_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"2025101409214465500_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin Oncol"},{"issue":"2","key":"2025101409214465500_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"8","key":"2025101409214465500_bib5","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1097\/HS9.0000000000000624","article-title":"Diagnostic next-generation sequencing frequently fails to detect MYD88(L265P) in Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Kofides","year":"2021","journal-title":"Hemasphere"},{"issue":"1","key":"2025101409214465500_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-025-01271-3","article-title":"Outcomes of patients with relapsed\/refractory lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia treated with venetoclax: a multicenter retrospective analysis","volume":"15","author":"Sawalha","year":"2025","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025101409214465500_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed \/refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1\/2 BRUIN study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025101409214465500_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2024-200277","article-title":"Iopofosine I 131 in previously treated patients with Waldenstr\u00f6m macroglobulinemia (WM): efficacy and safety results from the international, multicenter, open-label phase 2 study (CLOVER-WaM\u2122)","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025101409214465500_bib9","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1182\/blood-2024-211573","article-title":"A phase II trial of loncastuximab tesirine in patients with previously treated Waldenstr\u00f6m macroglobulinemia","volume":"144","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025101409214465500_bib10","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1182\/blood-2024-206415","article-title":"A phase 2 trial investigating epcoritamab in patients with previously treated Waldenstrom macroglobulinemia (WM)\/lymphoplasmacytic lymphoma (WM-NET3)","volume":"144","author":"von Keudell","year":"2024","journal-title":"Blood"},{"issue":"suppl 16","key":"2025101409214465500_bib11","doi-asserted-by":"crossref","first-page":"TPS7090","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7090","article-title":"BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstr\u00f6m macroglobulinemia [abstract]","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025101409214465500_bib12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2024-199212","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstr\u00f6m macroglobulinemia: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Seymour","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2025101409214465500_bib13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"33","key":"2025101409214465500_bib14","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025101409214465500_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025101409214465500_bib16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"2025101409214465500_bib17","author":"Palomba","year":"17-19  2024"},{"issue":"4","key":"2025101409214465500_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib discontinuation in Waldenstr\u00f6m macroglobulinemia: etiologies, outcomes, and IgM rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"2025101409214465500_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2025101409214465500_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-138725","article-title":"Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"issue":"24","key":"2025101409214465500_bib21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2025101409214465500_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood.2023022420","article-title":"Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naive Waldenstr\u00f6m macroglobulinemia","volume":"143","author":"Castillo","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2025101409214465500_bib23","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1182\/blood-2024-198297","article-title":"A phase II study of pirtobrutinib and venetoclax in previously treated patients with Waldenstr\u00f6m macroglobulinemia: an interim analysis","volume":"144","author":"Castillo","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4842\/2413838\/blooda_adv-2025-016890-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4842\/2413838\/blooda_adv-2025-016890-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:22:30Z","timestamp":1760448150000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4842\/546239\/Long-term-follow-up-of-venetoclax-monotherapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016890","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,25]]}}}